Access Patient Resources
Understanding the medical and pharmaceutical landscape is an essential – and oftentimes, first – step for any patient and their loved ones after a diagnosis. We've pulled together a wide range of informative resources on diseases, research, treatments, programs, coverage, and more to help patients at every step of their journey. Explore them below.
Chart Pack: Biopharmaceuticals in Perspective, Summer 2019
This chart pack provides facts and figures about prescription medicines and their role in the health care system.
Together - Migraine
Together - Asthma
130 medicines in development for asthma, allergies and other respiratory diseases
Keep the Six Protected Classes, protected
Medicare Part D has been successfully providing seniors with comprehensive drug coverage for more than a decade, and one of the cornerstones of the program has been to ensure the sickest and most vulnerable patients have access to the clinically critical medicines they rely on.
New whitepaper identifies reasons why ICER's cost-effectiveness analyses are not useful for payers
The whitepaper identifies several problems in applying ICER's reports to inform coverage decisions by private payers
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines
Together - CAR-T
Justin's story of resilience and hope are what inspire researchers like Boris to #GOBOLDLY every day and never stop searching for a cure to end cancer.
How much do you know about Medicare Part B?
As conversations about Medicare Part B continue, it's important to get the facts straight and ensure they are being put in context
Diversity of thought fuels next generation of breakthroughs
This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
With Asian Pacific American Heritage Month underway, we're taking some time to celebrate the diversity within our community and to acknowledge the many contributions Asian Americans (AAs), Native Hawaiians and Pacific Islanders (NHPIs) have made to ensure a better tomorrow for all Americans
Improve women's health by treating the disease, not the pain
Millions of women suffer from chronic, painful conditions that lack sufficient treatment options
PPA celebrates 13 years of helping patients access their medicines
Since launching in 2005, PPA has connected more than 10 million people to patient assistance programs (PAPs), which serve as critical safety nets for the millions of Americans who lack health insurance or whose insurance does not sufficiently cover the cost of the medicines they need
Improving care quality by engaging patients in shared decision making
With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient
Ask About Adherence: New study demonstrates how adherence programs can improve health outcomes for patients with cardiovascular disease
Recently, Health Affairs published a study that examined medication synchronization programs, which allow patients to collect all their medications in a single visit to the pharmacy, and their impact on cardiovascular medication adherence among Medicare beneficiaries
Biopharmaceutical Companies' Personalized Medicine Research Yields Innovative Treatments for Patients
The last five years have been characterized by increased momentum in personalized medicine.
Follow the Dollar Executive Summary
Drug pricing is a complex and often confusing issue, shaped by a payment system that involves numerous stakeholders.
Follow the Dollar: Flow of Payment for a $400 Insulin
Scott takes insulin for his type 2 diabetes and has a health plan with a high deductible.
Follow the Dollar: Janet
Janet is enrolled in a commercial health insurance plan and has a $40.00 copay for her blood pressure medicine.
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Together - ALS
Pat's words and optimism are what inspire researchers like Pablo to #GoBoldly every day and never stop searching for a cure to end ALS.
Medicines in Development for HIV 2017 Report
America's biopharmaceutical research companies are developing 52 medicines and vaccines for HIV.
List of Medicines in Development for HIV 2017
More than 50 medicines and vaccines are in development for HIV/AIDS infection treatment and prevention.
A critical opportunity to prevent prescription drug abuse
PREA and BPCA: Spurring Pediatric Drug Development
PREA and BPCA work together to foster pediatric drug development.
12 years of the Partnership of Prescription Assistance
Medicare Monday: A discussion on affordability and access to medicines
17 years (and more) of medical discoveries
How do multiple sclerosis patients define value?
ICYMI: New era of medicine initiative kicks off in Boston
Biopharmaceutical industry's success reducing disparities for African Americans
America's biopharmaceutical industry is central to diverse R&D ecosystem
Dr. Tim Garnett, CMO of Eli Lilly and Company, emphasizes that creating lifesaving medicines is the focus of the biopharmaceutical industry.
Actual versus projected death rates for HIV/AIDS in the U.S.
The introduction of HAART treatments caused a significant drop in the HIV/AIDS death rate.
Clinical Trials - What You Need to Know
Clinical trials are central to the work of biopharmaceutical researchers - they advance the science of bringing new medicines to the patients who need them.
Falling Death Rates for HIV/AIDS Patients
This data visualization provides a look at the actual vs projected death rates for HIV/AIDs in the United States.
Codes & Guidelines
Principles on Interactions with Patient Organizations
Biopharmaceutical companies share many common interests with patient organizations including a common commitment to patients and a shared mission to discover cures and fight disease.